FindTrial
Sign In

Prediction of Anthracycline-related Cardiac Damage in Childhood Acute Lymphoblastic Leukemia by Cardiodynamicsgram

Prediction of Anthracycline-related Cardiac Damage in Childhood Acute Lymphoblastic Leukemia by Cardiodynamicsgram

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500098659
Enrollment
Unknown
Registered
2025-03-12
Start date
2023-12-15
Completion date
Unknown
Last updated
2025-03-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute lymphoblastic leukemia

Interventions

children with ALL:NA

Sponsors

Qilu Hospital of Shandong University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 18 Years

Inclusion criteria

Inclusion criteria: 1.Age <18; 2.Diagnosed with acute lymphoblastic leukemia; 3.Plan to receive or have received anthracycline-based therapy regularly in our hospital; 4.The patient and family to informed consent for the research;

Exclusion criteria

Exclusion criteria: 1.Left ventricular ejection volume at baseline <50%; 2.Conditions that are not treated with the CCCG-ALL-2020 protocol, such as trisomy 21 syndrome, or congenital or hereditary diseases associated with organ impairment; 3.Secondary leukemia; 4.Heart disease or application of cardiotoxic drugs before chemotherapy; 5.Unable or unwilling to provide informed consent, key research materials of missing children;

Design outcomes

Secondary

MeasureTime frame
Anthracycline-related Cardiac Damage(ACD)-cardiac autonomic dysfunction;—

Primary

MeasureTime frame
Anthracycline-related Cardiac Damage(ACD)-change in cardiac function;—

Countries

China

Contacts

Public ContactAijun Zhang

Qilu Hospital of Shandong University

zhangaijun@sdu.edu.cn+86 531 82169950

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026